Interests in associates |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Interests in associates | |
| Interests in associates | 6. Interests in associates The European Medicines Agency’s recommended revocation of the TAVNEOS® marketing authorization led primarily to an impairment of intangible assets at Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) resulting in a decrease in the equity method investment’s profit in the amount of €172,466 for the three and six months ended June 30, 2026 with a corresponding proportionate decrease in the Company’s income from equity method investees. The carrying amount of the Company’s investment decreased by €3,298 from December 31, 2025 to June 30, 2026. |